GlassScriptPhysician profile
Karl Schwarze
NPI 1053426932
$5,547.06
in general payments reported to CMS, 2019-2025
25 companies · $441 in 2025
The $441 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $609 · 2021: $1,030 · 2022: $767 · 2023: $968 · 2024: $1,088 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409 · Education: $88.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,408.57 |
| Education | $88.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,151.39 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $609.44 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $550.16 | 2019-2025 | Jynarque |
| Amgen INC. | $502.53 | 2019-2025 | Krystexxa, Tavneos |
| Mallinckrodt Hospital Products INC. | $454.29 | 2020-2023 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $347.81 | 2021-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $204.96 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $201.83 | 2024-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $194.72 | 2021-2024 | Jesduvroq, Benlysta |
| Mallinckrodt Enterprises LLC | $190.06 | 2019 | |
| Travere Therapeutics, INC. | $149.37 | 2023-2025 | |
| Akebia Therapeutics INC | $136.56 | 2020-2021 | |
| Ardelyx, INC. | $133.47 | 2023-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $116.01 | 2019-2025 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $114.72 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $107.69 | 2019-2025 | Injectafer |
| Opko Pharmaceuticals, LLC | $82.14 | 2023-2025 | Rayaldee |
| Novo Nordisk INC | $74.44 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Vifor Pharma, INC. | $57.17 | 2021-2024 | Veltassa, Korsuva |
| Kyowa Kirin, INC. | $44.87 | 2024 | Crysvita |
| Renalytix Ai, INC. | $36.61 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Calliditas Therapeutics US INC. | $32.00 | 2024-2025 | Tarpeyo |
| Ultragenyx Pharmaceutical INC. | $27.94 | 2022 | |
| Outset Medical INC | $14.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.87 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Schwarze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.